ARA-290 vs Testoluten

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Organ-specific peptide complex targeting testicular Leydig and Sertoli cells. Modulates steroidogenic gene expression to support testosterone biosynthesis pathways.

Testoluten is a Khavinson-class peptide bioregulator derived from testicular tissue, developed as part of Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore gene expression and functional parameters in aging testicular tissue through peptide-chromatin regulatory element interaction rather than hormonal receptor agonism. As a testicular tissue-derived bioregulator, Testoluten is positioned within the Khavinson framework as a compound designed to modulate transcription in Leydig cells and Sertoli cells, potentially influencing testosterone biosynthesis, spermatogenesis, and testicular aging by reactivating gene expression programs that decline with age and environmental stress. Published research on the Khavinson peptide bioregulator class documents the systematic characterization of organ-specific short peptides and their proposed epigenetic mechanisms, with class-level evidence from animal models and human observational studies supporting the concept of peptide-mediated restoration of tissue-specific physiological parameters. Testoluten has no FDA approval and no approved indication in any Western jurisdiction; no indexed PubMed publications specifically report clinical outcomes for testoluten in controlled human studies, and the compound is available only through the Russian bioregulator market under the class-level evidence framework published by the Khavinson group.